Brain

PreveCeutical Welcomes Dr. Francis Tavares, PhD. As Chief Technology Officer

Vancouver, British Columbia--(Newsfile Corp. - June 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"),…

7 months ago

Axxess Partners With Zing Performance to Expand Access to Brain Health Solutions Through Home-Based Care

DALLAS, June 30, 2025 /PRNewswire/ -- Axxess, the leading global technology platform for healthcare at home, has partnered with Zing…

7 months ago

Danone North America Invests in the Future of Microbiome Science with 2024-2025 Fellowship Awards

Two graduate students receive grants supporting their research into the gut microbiome and probiotics in a program championing the next…

7 months ago

MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY

In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput…

7 months ago

Rewriting the Timeline of Detection: Linus Health’s Digital Platform Uncovers the Earliest Signs of Cognitive Decline

New research reveals that subtle response-time biomarkers—captured in minutes via digital assessments—can flag Alzheimer's and dementia risk far earlier than…

7 months ago

Apollo Biowellness, Inc., f/k/a Resonate Blends, Inc., Corporate Update

North Bergen, New Jersey--(Newsfile Corp. - June 26, 2025) - Apollo Biowellness, Inc. formerly known as Resonate Blends, Inc. (OTC…

7 months ago

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

Hybrid, decentralized trial of bezisterim in early Parkinson’s Disease prioritizes patient access and participationCARSON CITY, Nev., June 26, 2025 (GLOBE…

7 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated…

7 months ago

Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights

Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in…

7 months ago

Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

7 months ago